Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 1.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 179,578 shares of the biopharmaceutical company's stock after selling 1,850 shares during the period. Rhumbline Advisers owned approximately 0.14% of Alnylam Pharmaceuticals worth $42,256,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Huntington National Bank raised its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 45 shares in the last quarter. SYM FINANCIAL Corp increased its position in shares of Alnylam Pharmaceuticals by 6.2% during the 3rd quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 55 shares during the last quarter. Lindbrook Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company's stock valued at $157,000 after purchasing an additional 57 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock valued at $1,532,000 after purchasing an additional 58 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 2,650 shares of the biopharmaceutical company's stock valued at $624,000 after purchasing an additional 63 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ ALNY traded down $0.41 during mid-day trading on Friday, reaching $250.59. 653,580 shares of the company were exchanged, compared to its average volume of 693,794. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock has a market cap of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a 50-day moving average of $254.14 and a 200 day moving average of $263.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares of the company's stock, valued at approximately $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,356 shares of company stock worth $22,498,551 in the last three months. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a research report on Tuesday. Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, Barclays boosted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.